PTT-936 for Solid Tumors
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called PTT-936, which helps activate a protein to control tumor growth. It targets patients with advanced or spreading tumors. The drug may work better when combined with another treatment that boosts the immune system.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that patients on therapeutic anticoagulation must be on a stable dose for at least 14 days before starting the trial, which suggests some medications may need to be managed carefully.
What data supports the effectiveness of the drug PTT-936 for solid tumors?
Research shows that anti-PD-1/PD-L1 therapies, like those combined with PTT-936, have been effective in treating certain types of lung cancer by helping the immune system attack cancer cells. Additionally, similar treatments have shown promise in overcoming resistance to other cancer drugs, suggesting potential benefits for solid tumors.12345
What safety information is available for PTT-936 and related therapies?
The safety of therapies targeting the PD-1/PD-L1 pathway, which may include PTT-936, has been studied in various cancers. Common side effects are related to the immune system, affecting the skin and digestive system, but they are usually mild and manageable. Serious side effects, like autoimmune conditions, can occur but are less common.678910
Eligibility Criteria
Adults over 18 with advanced solid tumors that can't be surgically removed or have spread, who are able to follow the study plan. They should not need constant blood cell growth support and must have a life expectancy of at least 3 months. Their physical condition should allow normal activity or light work.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 Treatment
Determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 as a monotherapy
Phase 2a Treatment
Assessing the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Combination of PTT-936 and anti-PD-1/L1 therapy
- PTT-936
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pyrotech Therapeutics, Inc.
Lead Sponsor